about
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.A phase I study of volasertib combined with afatinib, in advanced solid tumors.Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.Helical tomotherapy in head and neck cancer: a European single-center experience.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.The role of taxanes and targeted therapies in locally advanced head and neck cancer.Recurrent head and neck cancer: current treatment and future prospects.Current concepts for the management of head and neck cancer: chemotherapy.Advances in the systemic treatment of head and neck cancers.Optimal treatment for recurrent/metastatic head and neck cancer.Bevacizumab in glioblastoma multiforme.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceIncorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer.Afatinib in squamous cell carcinoma of the head and neck.Ipilimumab in melanoma.Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation.Minerva's comment was not evidence based.Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients.Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.Ipilimumab in melanomaEORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaQuality of life in oropharyngeal cancer: a structured review of the literatureAuthors' response letter: Quality of life in oropharyngeal cancer: a structured review of the literature
P50
Q33387910-9F5B4374-3BBC-4DBC-AB8F-D861D381D41BQ33392240-CE2FF0C5-4759-445D-92AE-DB9971F78ADBQ33425698-13DFD766-A099-46C0-9558-A0C71FE3161BQ33434648-88255CD9-8117-4EB2-B783-5A1B7CBF0C43Q33491298-B6EE6458-9AF9-42D3-94B4-FB5D27236345Q35151101-92E6255F-20AC-4DAD-98E1-FD0F131D5DBFQ35584153-AE72ABC2-E326-4766-8BD2-E7B7C72D507AQ36030550-79EA3D15-D206-4C38-A603-7F286FC9F801Q36452263-88046A39-F1FD-4E3E-82C3-F39EBF7EC66AQ36783794-D8731DB7-4DF6-475C-BC22-DBC11BB97B4CQ37118936-EDAC61C0-CDFF-4489-8582-C23FE3AC363CQ37248145-0654C464-42E3-4750-BFF9-E8F93E7DB49CQ37692119-35CE6784-ACE7-473A-84AC-D36DB4FBB404Q37799934-1B99A780-A407-4440-97BD-0A9EC5FB37A7Q37965628-967ACFEE-5F9E-450F-AE2F-206D0EC5497FQ38118934-25381AEE-BDA5-4E42-84C1-E9FF152D1FDEQ38392336-94C16A0C-8F8E-4144-8B86-B9E31FD7CCB8Q38829891-7CBF7CAC-E52F-4EEB-9268-02FF6EDBAA96Q38893697-B73DEB87-C23E-4C4F-863E-CC8339D58913Q38959451-270DC7B3-6043-4356-BEB4-BAE34EBF6774Q42113451-EDCEA0F4-9C26-4929-9284-4BEB0A62D140Q42363121-301D9E3B-51D1-4F6F-9C6C-E6F7A7BBF6A6Q43188702-07CA8D97-4925-47DF-A02C-9CBBF0BBF527Q46244345-FEB062A3-66F4-4017-A2FF-0A59C0BA36BCQ48036615-E9099663-4080-4439-80A2-974A2A92D88DQ61866226-EF9AF2D9-36A2-4887-A236-4A6FF9573330Q61866232-DB79812F-EEF5-4630-B14E-2D122F426E45Q88564252-F20C2A20-1DD0-4060-B43F-EC21223232E9Q91569286-1667F7D1-3C98-4A67-972F-504B455E6965
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pol Specenier
@ast
Pol Specenier
@en
Pol Specenier
@es
Pol Specenier
@fr
Pol Specenier
@nl
Pol Specenier
@sl
type
label
Pol Specenier
@ast
Pol Specenier
@en
Pol Specenier
@es
Pol Specenier
@fr
Pol Specenier
@nl
Pol Specenier
@sl
prefLabel
Pol Specenier
@ast
Pol Specenier
@en
Pol Specenier
@es
Pol Specenier
@fr
Pol Specenier
@nl
Pol Specenier
@sl
P1053
E-1679-2014
P106
P1153
16203964000
P2038
Pol_Specenier
P21
P2798
P31
P3829
P496
0000-0002-2465-5197